

REMARKS

Applicants gratefully acknowledge the allowance of claims 1-5, 16, 17 and 21 in the office action dated February 6, 2008. Applicants' attorney would like to thank the Examiner for discussing the pending claims and the office action of February 6, 2008 with him on March 19, 2008. Specifically, Applicants' attorney would like to thank the Examiner for discussing the proposed amendments to claims in view of the 35 U.S.C. §112, first paragraph rejection of claims 6-8, 12-14, 18 and 20.

Amendments To The Claims

Claim 6 has been amended by addition of the phrase "bone fracture or bone defect, occurring individually or together, or of promoting bone in-growth" and by deletion, without waiver or prejudice, of the phrase "a PDE 2 mediated condition, disease or symptom." Support for this amendment is in the specification as filed, including original claims 6 and 7.

Claim 7 has been amended by limiting the condition being treated to bone fracture. Support for this amendment is in the specification as filed, including original claims 6 and 7.

Claim 8 has been amended by making it dependent on claim 7 rather than claim 6 and by specifying that the type of bone fracture being treated is delayed or non-union bone fracture.

Claim 18 has been amended by addition of the phrase "bone fracture or bone defect, occurring individually or together, or of promoting bone in-growth" and by deletion, without waiver or prejudice, of the phrase "a PDE 2 mediated condition, disease or symptom." Support for this amendment is in the specification as filed, including the original claims.

No new matter has been added by these amendments. Applicants reserve the right to file divisional or continuation applications, as appropriate, directed to the non-elected, canceled and deleted subject matter of this invention.

The 35 U.S.C. §112, first paragraph Rejection

Claims 6-8, 12-14, 18 and 20 have been rejected under 35 U.S.C. §112, first paragraph as allegedly not being enabled such that one skilled in the art could carry out the invention. The Examiner has admitted that the specification is enabling with respect to the treatment of bone fracture or the promotion of bone in-growth with compounds of examples 1-37 of formula (I).

The scope of claims 6-8, 12-14, 18 and 20 has been restricted to methods of treating bone fracture, bone defect, occurring individually or together, or promoting bone in-growth using compounds of formula (I) or in claims 12-14 using a compound of formula (I) and an EP<sub>2</sub> selective receptor agonist. The claims have been limited to subject matter related to that which the Examiner has acknowledged is enabled. Applicants respectfully submit that the claims, as amended, are fully enabled such that one skilled in the art could readily practice the invention. Applicants respectfully request that the Examiner reconsider claims 6-8, 12-14, 18 and 20, in view of the foregoing amendments, and withdraw the 35 U.S.C. §112, first paragraph rejection.

Entry of the foregoing amendments to the claims and consideration of the foregoing remarks is respectfully requested. An early and favorable response is respectfully solicited.

Respectfully submitted,

Date: 20 March 2008  
Pfizer Inc.  
Patent Department  
Eastern Point Road, MS 8260-1611  
Groton, Connecticut 06340  
(860) 715-6645

/ John A. Wichtowski /  
John A. Wichtowski  
Attorney for Applicant(s)  
Reg. No. 48,032